Marker Therapeutics(US:MRKR) Globenewswire·2025-11-03 14:15Core Insights - The Phase 1 APOLLO study of MT-601 in patients with relapsed B cell lymphomas has shown promising preliminary efficacy and a robust safety profile [1][2][3] Study Findings - MT-601 demonstrated an objective response rate (ORR) of 66% in Non-Hodgkin lymphoma (NHL) patients, with 50% achieving a complete response (CR) [2] - In Hodgkin lymphoma (HL), the ORR was 78%, with 11% achieving a CR [2] - Responses in NHL were durable, lasting from 3 to 24 months, with five patients remaining in remission for 6 months or longer [2] - The study reported no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) [1][2] Next Steps - The company has advanced to the dose expansion phase, evaluating MT-601 at the highest dose level (400x10 cells) in patients with Diffuse Large B Cell Lymphoma (DLBCL) [3] Presentation Details - Two posters will be presented at the 67th American Society of Hematology (ASH) Annual Meeting, detailing the safety and efficacy of MT-601 in relapsed or refractory Hodgkin and Non-Hodgkin lymphoma [4] About MT-601 - MT-601 is a multi-antigen recognizing (MAR) T cell therapy targeting six tumor antigens upregulated in lymphoma cells [5][6] - The therapy is being investigated for patients who have relapsed after or are not candidates for anti-CD19 CAR-T cell therapies [5][6] About APOLLO Trial - The APOLLO trial is a multicenter, open-label study designed to evaluate the safety and efficacy of MT-601 in participants with relapsed or refractory lymphoma [6] About MAR-T Cells - The MAR-T cell platform is a novel, non-genetically modified approach that selectively expands tumor-specific T cells capable of recognizing multiple tumor antigens [7] About Marker Therapeutics, Inc. - Marker Therapeutics is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [8]